Ligand Pharmaceuticals (NASDAQ: LGND) saw its stock price plummet by 5.06% in the pre-market trading session on Monday, March 3rd, 2025.
The drop in Ligand's share price can be attributed to the company's recently reported 2024 financial results and its acquisition of a royalty stake in Castle Creek Biosciences, a gene therapy company targeting a rare skin disease.
While Ligand reported a 27% increase in revenues and a 41% rise in adjusted earnings per share for 2024, the company's financial performance seems to have failed to meet investors' expectations. The company's guidance for 2025, projecting low-teens revenue growth and earnings per share of $6.00 to $6.25, also appears to have disappointed the market.
Additionally, Ligand's announcement of its participation in a $75 million royalty financing deal for Castle Creek Biosciences, aimed at supporting the latter's Phase III study of a gene therapy candidate for dystrophic epidermolysis bullosa (DEB), a rare skin disorder, has likely raised concerns among investors regarding the potential risks and returns associated with this investment.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.